Background: The antibacterial effect of piperacillin/sulbactam depends on the time of drug concentration above the minimal inhibitory concentration (MIC). Therefore, continuous infusion (CI) may be a more rational approach than standard intermittent short-term infusion (SI). The study investigated whether CI achieves effective drug concentrations comparable with SI. Methods: Seven intensive care unit patients received either piperacillin/sulbactam as 4/1 g intravenous infusion over 15–20 min every 8 h or as 4/1 g intravenous loading dose (15–20 min) followed by 8/2 g intravenous CI per 24 h. After 2 days, regimes were crossed over. Results: Pharmacokinetic parameters (mean ± SD) for SI piperacillin/sulbactam were: (1) peak serum concentration: piperacillin 231 ± 66 mg/l, sulbactam 53.1 ± 15.0 mg/l; (2) minimum serum concentration: piperacillin 11.5 ± 14.8 mg/l, sulbactam 4.2 ± 3.5 mg/l; (3) clearance: piperacillin 197 ± 72 ml/min (CI 269 ± 123 ml/min), sulbactam 167 ± 61 ml/min (CI 212 ± 109 ml/min); (4) half-life: piperacillin 2.4 ± 1.2 h, sulbactam 3.1 ± 1.6 h. Steady-state concentrations during CI were 25.5 ± 14.5 mg/l for piperacillin and 8.0 ± 3.7 mg/l for sulbactam. Average serum concentrations were comparable in both regimens. Conclusion: A large German survey demonstrated that approximately 89% of Pseudomonas aerugionsa have an MIC ≤16 mg/l and approximately 82% have an MIC ≤8 mg/l. According to this threshold, appropriate anti-bacterial concentrations of piperacillin/sulbactam were achievable with CI. CI dosing has the additional advantage that less drug is necessary. Further prospective studies are warranted to compare the clinical efficacy of CI and SI regimens in bacterial infections.

Keywords:
Piperacillin, Sulbactam, High-performance liquid chromatography, β-Lactam antibiotics, Time-dependent antibacterial activity, β-Lactamase inhibitor, Pharmacokinetics
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.